Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation

JAMA

Volumn 302, Issue 3, 2009, Pages 306-314

  Williams, Kirsten M ^a   Chien, Jason W ^b   Gladwin, Mark T ^c   Pavletic, Steven Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; AZITHROMYCIN; BUSULFAN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; AIRWAY OBSTRUCTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHIOLITIS OBLITERANS; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; SEROLOGY; TRANSBRONCHIAL BIOPSY; ADOLESCENT; ALLOTRANSPLANTATION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NEEDLE BIOPSY;

ADOLESCENT; BIOPSY, NEEDLE; BRONCHIOLITIS OBLITERANS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HOMOLOGOUS;

EID: 67651015068     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1018     Document Type: Article

References (80)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
2. Bhushan V, Collins RH Jr. Chronic graft-vs-host disease. JAMA. 2003;290(19):2599-2603.
3. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501-3506.
4. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008;2008:134-141.
5. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
6. Pavletic SZ, Martin P, Lee SJ, et al; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, IV: Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12(3):252-266.
7. Martin PJ, Weisdorf D, Przepiorka D, et al; Design of Clinical Trials Working Group. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, VI: Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006;12(5):491-505.
8. Clark JG. The challenge of bone marrow transplantation. Mayo Clin Proc. 1990;65(1):111-114.
9. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10):657-666.
10. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc. 2006;3(5):444-449.
11. Belperio JA, Lake K, Tazelaar H, Keane MP, Strieter RM, Lynch JP III. Bronchiolitis obliterans syndrome complicating lung or heart-lung transplantation. Semin Respir Crit Care Med. 2003;24(5):499-530.
12. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course. Ann Intern Med. 1989;111(5):368-376.
13. Santo Tomas LH, Loberiza FR Jr, Klein JP, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005;128(1):153-161.
14. Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant. 2004;33(5):509-517.
15. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood. 1988;72(2):621-627.
16. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med. 1987;107(5):648-656.
17. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28(5):425-434.
18. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168(2):208-214.
19. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol. 1995;26(6):668-675.
20. Philit F, Wiesendanger T, Archimbaud E, Mornex JF, Brune J, Cordier JF. Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J. 1995;8(4):551-558.
21. de Jong PA, Dodd JD, Coxson HO, et al. Bronchiolitis obliterans following lung transplantation: early detection using CT. Thorax. 2006;(May):2.
22. Schulman LL, Weinberg AD, McGregor CC, Suciu-Foca NM, Itescu S. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med. 2001;163(2):437-442.
23. Reynaud-Gaubert M, Thomas P, Badier M, Cau P, Giudicelli R, Fuentes P. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation: functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med. 2000;161(6):1924-1929.
24. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174(5):566-570.
25. Duncan SR, Leonard C, Theodore J, et al. Oligoclonal CD4(+) T cell expansions in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med. 2002;165(10):1439-1444.
26. Jaramillo A, Smith MA, Phelan D, et al. Temporal relationship between the development of anti-HLA antibodies and the development of bronchiolitis obliterans syndrome after lung transplantation. Transplant Proc. 1999;31(1-2):185-186.
27. Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol. 2009;182(1):309-318.
28. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2008;8(9):1911-1920.
29. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117(11):3498-3506.
30. Vanaudenaerde BM, Wuyts WA, Geudens N, et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant. 2007;7(1):76-82.
31. Botturi K, Lacoeuille Y, Thomas P, Boniface S, Reynaud-Gaubert M, Magnan A. CTLA-4-mediated regulatory phenotype of T-cells in tolerant lung recipients. Eur Respir J. 2008;31(6):1167-1176.
32. Mamessier E, Lorec AM, Thomas P, Badier M, Magnan A, Reynaud-Gaubert M. T regulatory cells in stable posttransplant bronchiolitis obliterans syndrome. Transplantation. 2007;84(7):908-916.
33. Bharat A, Fields RC, Steward N, Trulock EP, Patterson GA, Mohanakumar T. CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant. 2006;6(8):1799-1808.
34. Chamberlain D, Maurer J, Chaparro C, Idolor L. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant. 1994;13(6):963-971.
35. White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med. 2000;161(3 pt 1):723-729.
36. Suzuki T, Saijo Y, Ebina M, et al. Bilateral pneumothoraces with multiple bullae in a patient with asymptomatic bronchiolitis obliterans 10 years after bone marrow transplantation. Bone Marrow Transplant. 1999;23(8):829-831.
37. Chadwick C, Marven SM, Vora AJ. Autologous blood pleurodesis for pneumothorax complicating graft-versus-host disease-related bronchiolitis obliterans. Bone Marrow Transplant. 2004;33(4):451-453.
38. Kumar S, Tefferi A. Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation - case report and review of literature. Ann Hematol. 2001;80(7):430-435.
39. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other lateonset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(7):749-759.
40. Curtis DJ, Smale A, Thien F, Schwarer AP, Szer J. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;16(1):169-173.
41. Markopoulo KD, Cool CD, Elliot TL, et al. Obliterative bronchiolitis: varying presentations and clinicopathological correlation. Eur Respir J. 2002;19(1):20-30.
42. Chan CK, Hyland RH, Hutcheon MA, et al. Small-airways disease in recipients of allogeneic bone marrow transplants: an analysis of 11 cases and a review of the literature. Medicine (Baltimore). 1987;66(5):327-340.
43. Yokoi T, Hirabayashi N, Ito M, et al; Nagoya BMT Group. Broncho-bronchiolitis obliterans as a complication of bone marrow transplantation: a clinicopathological study of eight autopsy cases. Virchows Arch. 1997;431(4):275-282.
44. Parimon T, Madtes DK, Au DH, Clark JG, Chien JW. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med. 2005;172(3):384-390.
45. Sutedja TG, Apperley JF, Hughes JM, et al. Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia. Thorax. 1988;43(3):163-169.
46. Hansen JE, Sun XG, Wasserman K. Discriminating measures and normal values for expiratory obstruction. Chest. 2006;129(2):369-377.
47. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.
48. Cohen J, Postma DS, Vink-Klooster K, et al. FVC to slow inspiratory vital capacity ratio: a potential marker for small airways obstruction. Chest. 2007;132(4):1198-1203.
49. Nathell L, Nathell M, Malmberg P, Larsson K. COPD diagnosis related to different guidelines and spirometry techniques. Respir Res. 2007;8:89.
50. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003;54:29-52.
51. Diez Herranz A. RV/TLC% ratio: alternative criteria of normality. Eur Respir J. 1995;8(10):1812-1813.
52. Guttadauria M, Ellman H, Emmanuel G, Kaplan D, Diamond H. Pulmonary function in scleroderma. Arthritis Rheum. 1977;20(5):1071-1079.
53. Miller WT Jr, Kotloff RM, Blumenthal NP, Aronchick JM, Gefter WB, Miller WT. Utility of high resolution computed tomography in predicting bronchiolitis obliterans syndrome following lung transplantation: preliminary findings. J Thorac Imaging. 2001;16(2):76-80.
54. Choi YW, Rossi SE, Palmer SM, DeLong D, Erasmus JJ, McAdams HP. Bronchiolitis obliterans syndrome in lung transplant recipients: correlation of computed tomography findings with bronchiolitis obliterans syndrome stage. J Thorac Imaging. 2003;18(2):72-79.
55. Bankier AA, Van Muylem A, Knoop C, Estenne M, Gevenois PA. Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT. Radiology. 2001;218(2):533-539.
56. Leung AN, Fisher K, Valentine V, et al. Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. Chest. 1998;113(2):365-370.
57. Gunn ML, Godwin JD, Kanne JP, Flowers ME, Chien JW. High-resolution CT findings of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. J Thorac Imaging. 2008;23(4):244-250.
58. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21(3):297-310.
59. Fullmer JJ, Fan LL, Dishop MK, Rodgers C, Krance R. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics. 2005;116(3):767-770.
60. Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant. 2005;36(2):135-138.
61. Duncan CN, Buonanno MR, Barry EV, Myers K, Peritz D, Lehmann L. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(11):971-975.
62. Hollmén M, Tikkanen JM, Nykanen AI, Koskinen PK, Lemstrom KB. Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development. J Heart Lung Transplant. 2008;27(8):856-864.
63. Snell GI, Esmore DS, Williams TJ. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest. 1996;109(4):874-878.
64. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85(1):36-41.
65. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004;77(9):1465-1467.
66. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168(1):121-125.
67. Khalid M, Al Saghir A, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005;25(3):490-493.
68. Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005;172(6):772-775.
69. Verleden GM, Dupont LJ, Vanhaecke J, Daenen W, Van Raemdonck DE. Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report. J Heart Lung Transplant. 2005;24(8):1155-1158.
70. Porhownik NR, Batobara W, Kepron W, Unruh HW, Bshouty Z. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J. 2008;15(4):199-202.
71. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 2005;24(9):1440-1443.
72. Smith EP, Sniecinski I, Dagis AC, et al. Extracorporeal photochemotherapy for treatment of drugresistant graft-vs-host disease. Biol Blood Marrow Transplant. 1998;4(1):27-37.
73. Besnier DP, Chabannes D, Mahe B, et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation. 1997;64(1):49-54.
74. Ilhan O, Arat M, Arslan O, et al. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apheresis Sci. 2004;30(3):185-187.
75. Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med. 2003;167(9):1271-1278.
76. Islam SA, Thomas SY, Hess C, et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood. 2006;107(2):444-453.
77. Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest. 1996;97(8):1827-1836.
78. Medoff BD, Seung E, Wain JC, et al. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med. 2005;202(1):97-110.
79. Or R, Gesundheit B, Resnick I, et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation. 2007;83(5):577-581.
80. Couriel D, Carpenter PA, Cutler C, et al; Ancillary Therapy and Supportive Care Working Group Report. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease, V: Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant. 2006;12(4):375-396.